Weekly administration of docetaxel in patients with hormone-refractory prostate cancer

A pilot study on Japanese patients

Takahiro Kojima, Toru Shimazui, Mizuki Onozawa, Sadamu Tsukamoto, Shiro Hinotsu, Naoto Miyanaga, Kazunori Hattori, Koji Kawai, Hideyuki Akaza

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: Although treatment of hormone-refractory prostate cancer (HRPC) is difficult, a single-agent weekly dose of docetaxel has been reported as a promising regimen for patients with HRPC. The purpose of this study was the investigation of the efficacy of docetaxel for Japanese patients with HRPC. Methods: Ten patients with HRPC were treated with weekly docetaxel at Tsukuba University Hospital and were evaluated for the responses with respect to serum prostate-specific antigen (PSA), tumor size and survival. Considering the ethnic balance, the dose of docetaxel was reduced to 30 mg/m2 weekly compared with 36 mg/m2 in the study reported previously. Results: A biochemical response (> 50% decrease in PSA) was observed in five patients (56%; 5/9) with an average time to progression of 4.5 months. In two partial responders as determined by PSA, respective metastatic lesions in bone and soft tissue were also improved. The estimated median survival duration was 6 months. Most of these responses were accompanied by a significant reduction in the requirement for analgesic agents. No severe toxicity of this regimen was observed, except for gastric ulcer in one patient who was excluded from the evaluation. Conclusions: Weekly administration of docetaxel as a single agent was associated with a high rate of PSA reduction. This treatment is feasible for patients with HRPC, even those who have a poor performance status and extensive prior treatments.

Original languageEnglish
Pages (from-to)137-141
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume34
Issue number3
DOIs
Publication statusPublished - Mar 1 2004
Externally publishedYes

Fingerprint

docetaxel
Prostatic Neoplasms
Hormones
Prostate-Specific Antigen
Survival
Stomach Ulcer
Analgesics
Therapeutics

Keywords

  • Docetaxel
  • Hormone refractory
  • Prostate cancer
  • Weekly

ASJC Scopus subject areas

  • Oncology

Cite this

Weekly administration of docetaxel in patients with hormone-refractory prostate cancer : A pilot study on Japanese patients. / Kojima, Takahiro; Shimazui, Toru; Onozawa, Mizuki; Tsukamoto, Sadamu; Hinotsu, Shiro; Miyanaga, Naoto; Hattori, Kazunori; Kawai, Koji; Akaza, Hideyuki.

In: Japanese Journal of Clinical Oncology, Vol. 34, No. 3, 01.03.2004, p. 137-141.

Research output: Contribution to journalArticle

Kojima, T, Shimazui, T, Onozawa, M, Tsukamoto, S, Hinotsu, S, Miyanaga, N, Hattori, K, Kawai, K & Akaza, H 2004, 'Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: A pilot study on Japanese patients', Japanese Journal of Clinical Oncology, vol. 34, no. 3, pp. 137-141. https://doi.org/10.1093/jjco/hyh021
Kojima, Takahiro ; Shimazui, Toru ; Onozawa, Mizuki ; Tsukamoto, Sadamu ; Hinotsu, Shiro ; Miyanaga, Naoto ; Hattori, Kazunori ; Kawai, Koji ; Akaza, Hideyuki. / Weekly administration of docetaxel in patients with hormone-refractory prostate cancer : A pilot study on Japanese patients. In: Japanese Journal of Clinical Oncology. 2004 ; Vol. 34, No. 3. pp. 137-141.
@article{f363a84580fa45f4b7d60fb6e29aadeb,
title = "Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: A pilot study on Japanese patients",
abstract = "Objective: Although treatment of hormone-refractory prostate cancer (HRPC) is difficult, a single-agent weekly dose of docetaxel has been reported as a promising regimen for patients with HRPC. The purpose of this study was the investigation of the efficacy of docetaxel for Japanese patients with HRPC. Methods: Ten patients with HRPC were treated with weekly docetaxel at Tsukuba University Hospital and were evaluated for the responses with respect to serum prostate-specific antigen (PSA), tumor size and survival. Considering the ethnic balance, the dose of docetaxel was reduced to 30 mg/m2 weekly compared with 36 mg/m2 in the study reported previously. Results: A biochemical response (> 50{\%} decrease in PSA) was observed in five patients (56{\%}; 5/9) with an average time to progression of 4.5 months. In two partial responders as determined by PSA, respective metastatic lesions in bone and soft tissue were also improved. The estimated median survival duration was 6 months. Most of these responses were accompanied by a significant reduction in the requirement for analgesic agents. No severe toxicity of this regimen was observed, except for gastric ulcer in one patient who was excluded from the evaluation. Conclusions: Weekly administration of docetaxel as a single agent was associated with a high rate of PSA reduction. This treatment is feasible for patients with HRPC, even those who have a poor performance status and extensive prior treatments.",
keywords = "Docetaxel, Hormone refractory, Prostate cancer, Weekly",
author = "Takahiro Kojima and Toru Shimazui and Mizuki Onozawa and Sadamu Tsukamoto and Shiro Hinotsu and Naoto Miyanaga and Kazunori Hattori and Koji Kawai and Hideyuki Akaza",
year = "2004",
month = "3",
day = "1",
doi = "10.1093/jjco/hyh021",
language = "English",
volume = "34",
pages = "137--141",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Weekly administration of docetaxel in patients with hormone-refractory prostate cancer

T2 - A pilot study on Japanese patients

AU - Kojima, Takahiro

AU - Shimazui, Toru

AU - Onozawa, Mizuki

AU - Tsukamoto, Sadamu

AU - Hinotsu, Shiro

AU - Miyanaga, Naoto

AU - Hattori, Kazunori

AU - Kawai, Koji

AU - Akaza, Hideyuki

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Objective: Although treatment of hormone-refractory prostate cancer (HRPC) is difficult, a single-agent weekly dose of docetaxel has been reported as a promising regimen for patients with HRPC. The purpose of this study was the investigation of the efficacy of docetaxel for Japanese patients with HRPC. Methods: Ten patients with HRPC were treated with weekly docetaxel at Tsukuba University Hospital and were evaluated for the responses with respect to serum prostate-specific antigen (PSA), tumor size and survival. Considering the ethnic balance, the dose of docetaxel was reduced to 30 mg/m2 weekly compared with 36 mg/m2 in the study reported previously. Results: A biochemical response (> 50% decrease in PSA) was observed in five patients (56%; 5/9) with an average time to progression of 4.5 months. In two partial responders as determined by PSA, respective metastatic lesions in bone and soft tissue were also improved. The estimated median survival duration was 6 months. Most of these responses were accompanied by a significant reduction in the requirement for analgesic agents. No severe toxicity of this regimen was observed, except for gastric ulcer in one patient who was excluded from the evaluation. Conclusions: Weekly administration of docetaxel as a single agent was associated with a high rate of PSA reduction. This treatment is feasible for patients with HRPC, even those who have a poor performance status and extensive prior treatments.

AB - Objective: Although treatment of hormone-refractory prostate cancer (HRPC) is difficult, a single-agent weekly dose of docetaxel has been reported as a promising regimen for patients with HRPC. The purpose of this study was the investigation of the efficacy of docetaxel for Japanese patients with HRPC. Methods: Ten patients with HRPC were treated with weekly docetaxel at Tsukuba University Hospital and were evaluated for the responses with respect to serum prostate-specific antigen (PSA), tumor size and survival. Considering the ethnic balance, the dose of docetaxel was reduced to 30 mg/m2 weekly compared with 36 mg/m2 in the study reported previously. Results: A biochemical response (> 50% decrease in PSA) was observed in five patients (56%; 5/9) with an average time to progression of 4.5 months. In two partial responders as determined by PSA, respective metastatic lesions in bone and soft tissue were also improved. The estimated median survival duration was 6 months. Most of these responses were accompanied by a significant reduction in the requirement for analgesic agents. No severe toxicity of this regimen was observed, except for gastric ulcer in one patient who was excluded from the evaluation. Conclusions: Weekly administration of docetaxel as a single agent was associated with a high rate of PSA reduction. This treatment is feasible for patients with HRPC, even those who have a poor performance status and extensive prior treatments.

KW - Docetaxel

KW - Hormone refractory

KW - Prostate cancer

KW - Weekly

UR - http://www.scopus.com/inward/record.url?scp=2342455763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342455763&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyh021

DO - 10.1093/jjco/hyh021

M3 - Article

VL - 34

SP - 137

EP - 141

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 3

ER -